Mitsubishi UFJ Asset Management UK Ltd. Trims Holdings in LivaNova PLC (NASDAQ:LIVN)

Key Points

• Mitsubishi UFJ Asset Management UK Ltd. has decreased its holdings in LivaNova PLC by 73.7%, owning only 5,000 shares after selling 14,000 in the first quarter.
• The company's reported earnings per share (EPS) for the last quarter were $1.05, surpassing the consensus estimate of $0.84 and marking a revenue increase of 10.6% compared to the previous year.
• Analysts maintain a mostly positive outlook on LivaNova, with an average rating of "Buy" and a consensus price target of $59.29.

Mitsubishi UFJ Asset Management UK Ltd. decreased its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 73.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,000 shares of the company's stock after selling 14,000 shares during the period. Mitsubishi UFJ Asset Management UK Ltd.'s holdings in LivaNova were worth $196,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of LIVN. Caitong International Asset Management Co. Ltd increased its stake in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock valued at $58,000 after buying an additional 1,184 shares during the period. Russell Investments Group Ltd. increased its stake in shares of LivaNova by 4,581.9% during the first quarter. Russell Investments Group Ltd. now owns 70,322 shares of the company's stock valued at $2,762,000 after buying an additional 68,820 shares during the period. Nuveen LLC purchased a new position in shares of LivaNova during the first quarter valued at $30,954,000. Invesco Ltd. increased its stake in shares of LivaNova by 13.4% during the first quarter. Invesco Ltd. now owns 126,266 shares of the company's stock valued at $4,960,000 after buying an additional 14,892 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of LivaNova by 890.9% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 105,059 shares of the company's stock valued at $4,127,000 after buying an additional 94,457 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $53.06 on Thursday. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $57.35. The company has a market cap of $2.90 billion, a PE ratio of -13.64 and a beta of 0.92. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The business has a 50-day simple moving average of $45.36 and a two-hundred day simple moving average of $42.87.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. The firm had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%. The company's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share. As a group, equities analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LIVN has been the topic of several research reports. Barclays cut their price target on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research note on Tuesday, May 20th. Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Robert W. Baird raised their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.